Outlier testing has a long and checkered history in the pharmaceutical/biopharmaceutical industry, and has undergone close regulatory scrutiny since the Barr decision (U.S.A. vs. Barr Labs, 1993).  This talk will include some basic observations on the philosophy and practice of outlier testing and proceed to the development of a novel outlier test for plate based relative potency dilution bioassays with limited replication.